NanoDimension adding European focus for new $335M fund

NanoDimension intends to make its first-ever investments in Europe from its new $335 million third fund, with far more global emphasis on drug development than its previous funds have had.

The California-based firm has established an office in Lausanne, Switzerland, from which two partners will manage investments. European and American LPs, including family offices as well as undisclosed institutional investors, contributed to the fund, which is more than twice the size of NanoDimension’s last vehicle. Two partners in California will continue to shepherd U.S. investments...